Scholarlink

Background <p>Selective serotonin reuptake inhibitors (SSRIs) are frequently co-prescribed with opioids, increasing the risk of pharmacokinetic and pharmacodynamic interactions. Hydrocodone, a commonly prescribed opioid metabolized by cytochrome (CYP) 2D6 and CYP3A4, may be affected by enzyme inhibition from certain SSRIs. However, it remains unclear whether all SSRIs pose equal overdose risk or if some may be safer options for patients requiring both medications. Thus, we aimed to evaluate comparative risks of opioid overdose among patients initiating SSRIs while on hydrocodone.</p> Methods <p>This population-based cohort study utilized US public and commercial health insurance claims data from 2004 to 2022 and included patients who initiated a SSRI (citalopram, escitalopram, fluoxetine, paroxetine, or sertraline) while receiving hydrocodone treatment. The outcome was hospitalization or emergency department visit due to opioid overdose. We balanced baseline covariates via propensity score matching weights. A weighted Cox proportional hazards model compared rates across the five SSRIs.</p> Results <p>Among 1,486,583 patients who initiated an SSRI while on hydrocodone, 403,488 (27.1%) initiated sertraline, 348,484 (23.4%) initiated citalopram, 311,375 (21.0%) initiated escitalopram, 258,957 (17.4%) initiated fluoxetine, and 164,279 (11.1%) initiated paroxetine. During a median on-treatment follow-up of 28&#xa0;days, 1500 primary endpoints occurred. Weighted hazard ratios (HRs) for opioid overdose, using sertraline as the reference, were 1.21 (95% CI 1.02–1.42) for citalopram, 1.19 (1.00–1.41) for escitalopram, 1.29 (1.09–1.54) for fluoxetine, and 1.17 (0.95–1.43) for paroxetine. Using citalopram as the reference, HRs were 0.99 (0.83–1.17) for escitalopram, 1.07 (0.91–1.27) for fluoxetine, and 0.97 (0.79–1.18) for paroxetine. Relative to escitalopram, HRs were 1.09 (0.92–1.30) for fluoxetine and 0.98 (0.80–1.20) for paroxetine, and relative to fluoxetine, the HR was 0.90 (0.74–1.10) for paroxetine. Comparisons among SSRIs other than sertraline showed similar risks of overdose. Intention-to-treat analysis yielded similar findings, although the associations were attenuated.</p> Conclusions <p>In this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Sungho Bea,
  • Krista F. Huybrechts,
  • Robert J. Glynn,
  • Seanna M. Vine,
  • Shruti Belitkar,
  • Brian T. Bateman,
  • Katsiaryna Bykov

摘要

Background

Selective serotonin reuptake inhibitors (SSRIs) are frequently co-prescribed with opioids, increasing the risk of pharmacokinetic and pharmacodynamic interactions. Hydrocodone, a commonly prescribed opioid metabolized by cytochrome (CYP) 2D6 and CYP3A4, may be affected by enzyme inhibition from certain SSRIs. However, it remains unclear whether all SSRIs pose equal overdose risk or if some may be safer options for patients requiring both medications. Thus, we aimed to evaluate comparative risks of opioid overdose among patients initiating SSRIs while on hydrocodone.

Methods

This population-based cohort study utilized US public and commercial health insurance claims data from 2004 to 2022 and included patients who initiated a SSRI (citalopram, escitalopram, fluoxetine, paroxetine, or sertraline) while receiving hydrocodone treatment. The outcome was hospitalization or emergency department visit due to opioid overdose. We balanced baseline covariates via propensity score matching weights. A weighted Cox proportional hazards model compared rates across the five SSRIs.

Results

Among 1,486,583 patients who initiated an SSRI while on hydrocodone, 403,488 (27.1%) initiated sertraline, 348,484 (23.4%) initiated citalopram, 311,375 (21.0%) initiated escitalopram, 258,957 (17.4%) initiated fluoxetine, and 164,279 (11.1%) initiated paroxetine. During a median on-treatment follow-up of 28 days, 1500 primary endpoints occurred. Weighted hazard ratios (HRs) for opioid overdose, using sertraline as the reference, were 1.21 (95% CI 1.02–1.42) for citalopram, 1.19 (1.00–1.41) for escitalopram, 1.29 (1.09–1.54) for fluoxetine, and 1.17 (0.95–1.43) for paroxetine. Using citalopram as the reference, HRs were 0.99 (0.83–1.17) for escitalopram, 1.07 (0.91–1.27) for fluoxetine, and 0.97 (0.79–1.18) for paroxetine. Relative to escitalopram, HRs were 1.09 (0.92–1.30) for fluoxetine and 0.98 (0.80–1.20) for paroxetine, and relative to fluoxetine, the HR was 0.90 (0.74–1.10) for paroxetine. Comparisons among SSRIs other than sertraline showed similar risks of overdose. Intention-to-treat analysis yielded similar findings, although the associations were attenuated.

Conclusions

In this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline.